Pleural/pericardic effusions during dasatinib treatment: Incidence, management and risk factors associated to their development

Expert Opinion on Drug Safety

Volumn 9, Issue 5, 2010, Pages 713-721

  Breccia, Massimo ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chronic myeloid leukemia; Dasatinib; Pericardic effusion; Pleural effusion

Indexed keywords

BCR ABL PROTEIN; DASATINIB; DIURETIC AGENT; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; STEROID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMORBIDITY; CYTOPENIA; DIARRHEA; DISEASE PREDISPOSITION; DONOR LYMPHOCYTE INFUSION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FLUID RETENTION; GENE MUTATION; HEALTH CARE PERSONNEL; HEART FAILURE; HUMAN; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOSIS; MAXIMUM TOLERATED DOSE; MORBIDITY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATHOGENESIS; PATIENT MONITORING; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; PLEURODESIS; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SIDE EFFECT; THORACOCENTESIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; DRUG ERUPTIONS; HUMANS; HYPERCHOLESTEROLEMIA; INCIDENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTE COUNT; PERICARDIAL EFFUSION; PIPERAZINES; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RISK FACTORS; THIAZOLES; TREATMENT OUTCOME;

EID: 77955942528     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740331003742935     Document Type: Review

References (55)

1. Goldman JM, Melo JV. Chronic myeloid leukemia-advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-1464
2. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 2004;5:33-44
3. Hehlmann R, Hochhaus A, Baccarani M; European LeukemiaNet. Chronic myeloid leukaemia. Lancet 2007;370:342-350
4. Faderl S, Talpaz M, Estrov Z, Kantarjian H. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207-219
5. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1 positive chronic myeloid leukaemia. Blood 2009;113:1619-1630
6. Melo JV, Deininger MW. Biology of chronic myelogenous leukaemia-signaling pathways of initiation and transformation. Hematol Oncol Clin North Am 2004;18:545-568
7. Garcia-Manero G, Faderl S, OBrien S, et al. Chronic myelogenous leukaemia: a review and update of therapeutic strategies. Cancer 2003;98:437-457
8. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001;344:1031-1037
9. Johnson JR, Bross P, Cohen M, et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase. Clin Cancer Res 2003;9:1972-1979
10. Deininger MW, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 2005;105:2640-2653
11. OBrien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM). Blood 2008;112:abstract 186
12. Deininger MW, OBrien SG, Guilhot F, et al. International randomized study of interferon vs STI571(IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009;114:1126
13. Breccia M, Alimena G. Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem. Cardiovasc Hematol Disord Drug Targets 2009;9:21-28
14. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1018-1029
15. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 2007;8:1116-1128
16. Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett 2007;249:121-132
17. Milojkovic D, Apperley JF. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukaemia. Clin Cancer Res 2009;15:7519-7527
18. Irvine DA, Heaney NB, Holyoake TL. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors-A synthesis of clinical and laboratory data. Blood Rev 2009;24:1-9
19. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance and mutations in the ATP phosphate-binding loop (p-loop) are associated with a poor prognosis. Blood 2003;102:276-283
20. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukaemia treated with imatinib mesylate. Leukemia 2006;20:1767-1773
21. Soverini S, Colarossi S, Gnani A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-7379
22. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukaemia patients: a retrospective analysis fron the French intergroup of CML. Leukemia 2006;20:1061-1066
23. Sherbenou DW, Wong MJ, Humayun A, et al. Mutations of the BCR-ABL kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007;21:489-493
24. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukaemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806-4813
25. Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs 2008;22:59-69
26. Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opin Investig Drugs 2007;16:679-687
27. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia. Clin Ther 2007;29:2289-2308
28. Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 2009;4:3-10
29. Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol 2007;18(Suppl 6):vi42-46
30. Giles FJ, ODwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009;23:1698-1707
31. OHare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008;17:865-878
32. Shah NP. Dasatinib. Drugs Today (Barc) 2007;43:5-12
33. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352-359
34. Pavlù J, Marin D. Dasatinib and chronic myeloid leukaemia: two-year follow-up in eight clinical trials. Clin Lymphoma Myeloma 2009;9:417-424
35. Hochhaus A, Kantarjian H, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukaemia after failure of imatinib therapy. Blood 2007;109:2303-2309
36. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008;22:1200-1206
37. Kantarjian H, Pasquini R, Leévy V, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009;115:3935-3943
38. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A Trial. J Clin Oncol 2009;27:3472-3479
39. Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008;22:2176-2183
40. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212
41. Saglio G, Kantarjian H, Hochhaus A, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035. Blood 2008;112:3226
42. Ocheni S, Iwanski GB, Schafhausen P, et al. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation. Leuk Lymphoma 2009;50:551-558
43. Kelly K, Swords R, Mahalingam D, et al. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 2009;4(2):99-105
44. Porkka K, Khoury HJ, Paquette R, et al. Dasatinib 100 mg once daily (QD) maintains long-term efficacy and minimizes the occurrence of pleural effusion: an analysis of 24-month data in patients with resistance, suboptimal response, or intolerance to imatinib (CA180-034). Blood 2008;112:3242
45. Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010;116:377-386
46. Cortes J, Joned D, OBrien S, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010;28:398-404
47. Zwaan CM, Rizzari C, van der Velden VHJ, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: interim results of the CA180-018 phase I study from the ITCC consortium. Blood 2008;112:3241
48. Quintás-Cardama A, Kantarjian H, Obrien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-3914
49. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008;141:745-747
50. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009;23:1398-1405
51. Mustjoki S, Kreutzman A, Dix C, et al. Large granular lymphocyte (LGL) expansions comprising oligiclonal T cell or NK cell populations in dasatinib treated patients are associated with HLA-A 0201, CMV reactivation and enhanced anti-leukemic control. Blood 2009;114:abstract 1123
52. Valent J, Schiffer CA. Prevalence of large granular lymphocyte proliferation in chronic myeloid leukemia (CML) patients treated with dasatinib. Blood 2009;114:abstract 1111
53. Russo Rossi A, Ricco A, Carluccio P, et al. T/NK lymphocytosis in CML Ph+ patients during dasatinib therapy. Blood 2009;114:abstract 3279
54. Breccia M, Latagliata R, Stagno F, et al. Comorbidities influence compliance and development of pleural effusions in elderly chronic myeloid leukemia (CML) patients treated with dasatinib. Haematologica 2009;94:s4-abstract 100
55. la Rosee P, Leitner A, Martiat P, et al. Weekend drug holiday of dasatinib in CML patients not tolerating standard dosing regimens. Reducing toxicity with maintained disease control. Blood 2009;114:1119